Clinical trial
Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer
NCT00005076 · University of Alabama at Birmingham, Other · Completed
Key facts
| NCT number | NCT00005076 |
|---|---|
| Title | Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer |
| Official title | Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody Cetuximab in Combination With Chemotherapy in Patients With Advanced Colorectal Carcinoma |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, irinotecan hydrochloride |
| Enrollment | 110 |
| Start date | Oct 1, 1999 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Aug 9, 2004 |
| Last update posted | Apr 12, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: